Abstract 18075: Cardiovascular Events and Mortality After KRAS Inhibitor Therapy Discontinuation in Patients with Non-Small Cell Lung Cancer
Background: KRAS inhibitors, including Sotorasib and Adagrasib, have expanded treatment options for patients with KRAS-mutated non small cell lung cancer (NSCLC). However, cardiovascular outcomes after KRAS inhibitor initiation remain poorly characterized. Hypothesis: We hypothesized that cardiovascular events...